Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms

Anna Pellat,Chantal Dreyer,Camille Couffignal,Thomas Walter,Catherine Lombard-Bohas,P. Niccoli,Jean-François Seitz,Olivia Hentic,Thierry André,Romain Coriat,Sandrine Faivre,Magaly Zappa,Philippe Ruszniewski,Nicolas Poté,Anne Couvelard,Eric Raymond

Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms

2018

Anna Pellat
Chantal Dreyer
Camille Couffignal
Thomas Walter
Catherine Lombard-Bohas
P. Niccoli
Jean-François Seitz
Olivia Hentic
Thierry André
Romain Coriat
Sandrine Faivre
Magaly Zappa
Philippe Ruszniewski
Nicolas Poté
Anne Couvelard
Eric Raymond

Background/Aims: Angiogenesis is extensively developed in well-differentiated pancreatic neuroendocrine tumours (PanNET) where sunitinib was shown to prolong prog

Keywords:

Angiogenesis
Endocrinology
Biomarker (medicine)
Internal medicine
Biology
Sunitinib
Ki-67
Dosing
Immunohistochemistry
Diabetes mellitus
Toxicity
Oncology
Pharmacokinetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations